ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of December 31, 2023
18 January 2024 - 4:00AM
Business Wire
Regulatory News:
ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical
stage biopharmaceutical company developing glenzocimab, an
innovative drug for the treatment of cardiovascular emergencies,
today discloses the total number of voting rights and shares as of
December 31, 2023 (pursuant to Article L. 233-8 II of the French
Commercial Code and Article 223-16 of the General Regulation of the
French Financial Markets Authority).
- Listing Place: Euronext Growth Paris
- ISIN Code : FR0014005OJ5
- Web site: acticor-biotech.com
Date
Number of shares making up the
share capital
Theoretical number of voting
rights (1)
Number of voting rights excluding
shares stripped of voting rights (2)
December 31, 2023
13.189.141
13.189.141
13.124.019
(1) In accordance with Article 223-111 of the
AMF’s General Regulation, this number of shares is calculated based
on all shares carrying the right to vote, including those stripped
of voting rights.
(2) The actual voting rights correspond to
the total number of voting rights that can be exercised in a
general meeting. They are calculated on the basis of the total
number of voting rights attached to the total number of shares
minus the shares without voting rights.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a
spin-off from INSERM (the French National Institute of Health and
Medical Research), which is aiming to develop an innovative
treatment for cardiovascular emergencies, including ischemic
stroke.
The positive results of the phase 1b/2a study, ACTIMIS,
confirmed the safety profile of glenzocimab and showed a reduction
in mortality and intracerebral hemorrhage in the
glenzocimab-treated group of stroke patients. These results were
confirmed by a post-hoc analysis of brain imaging at 0 and 24 hours
using artificial intelligence (Brainomix, UK). This independent
analysis confirmed the reduction in the number and volume of
intracerebral lesions in patients treated with glenzocimab. The
efficacy of glenzocimab is now being analyzed in an international
Phase 2/3 study, ACTISAVE, with clinical results expected in Q2
2024.
In July 2022, Acticor Biotech was granted "PRIME" status by the
European Medicines Agency (EMA) for glenzocimab in the treatment of
stroke. This designation will allow the company to strengthen its
interactions and obtain early dialogues with regulatory
authorities.
Acticor Biotech is supported by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation).
Acticor Biotech is listed on Euronext Growth Paris since November
2021 (ISIN: FR0014005OJ5 – ALACT).
For more information, visit: www.acticor-biotech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117858900/en/
ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder
gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD General Manager and CSO
Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN / Quentin MASSÉ Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Acticor Biotech (EU:ALACT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acticor Biotech (EU:ALACT)
Historical Stock Chart
From Apr 2023 to Apr 2024
